Matilde Bjørn Ørum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matilde Bjørn Ørum has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Alex Lund Laursen
Department of Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark
1 shared publication- Anne Troldborg
Aarhus University Hospital
1 shared publication Elisabeth Bendstrup
Institute of Clinical Medicine Aarhus University Aarhus Denmark
1 shared publicationFrederikke F. Rönsholt
Department of Cardiology, Section for Lung Transplantation University Hospital Rigshospitalet Copenhagen Kobenhavn Denmark
1 shared publication- Krestine Corydon
Department of Internal Medicine, Gødstrup Regional Hospital, Herning, Denmark
1 shared publication - Kristina Öbrink-Hansen
Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark
1 shared publication
Latest Publications
- 19 September 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (9) , e260624
Progressive multifocal leukoencephalopathy in systemic lupus erythematosus treated with pembrolizumab
This case report discusses a patient with systemic lupus erythematosus (SLE) treated with low-dose azathioprine who developed progressive multifocal leukoencephalopathy (PML). PML is a rare, severe, demyelinating disease linked to John Cunningham polyomavirus (JCV) reactivation. Treated with pembrolizumab, an immune checkpoint inhibitor, the patient initially improved. However, after the fourth dose, her condition rapidly worsened resulting in treatment discontinuation and death. Similar cases highlight the complex interplay of factors in PML development in SLE patients, including immunosuppression and genetic factors. The use of pembrolizumab in PML and SLE necessitates careful consideration of potential complications.
- 19 September 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (9) , e260624
Progressive multifocal leukoencephalopathy in systemic lupus erythematosus treated with pembrolizumab
This case report discusses a patient with systemic lupus erythematosus (SLE) treated with low-dose azathioprine who developed progressive multifocal leukoencephalopathy (PML). PML is a rare, severe, demyelinating disease linked to John Cunningham polyomavirus (JCV) reactivation. Treated with pembrolizumab, an immune checkpoint inhibitor, the patient initially improved. However, after the fourth dose, her condition rapidly worsened resulting in treatment discontinuation and death. Similar cases highlight the complex interplay of factors in PML development in SLE patients, including immunosuppression and genetic factors. The use of pembrolizumab in PML and SLE necessitates careful consideration of potential complications.
- Open Access
- 3 May 2024
- Published by Hindawi Limited in Case Reports in Infectious Diseases
- Vol. 2024, 1-3
Diagnostic Delay of Spinal Tuberculosis Causing Medullary Compression
We present a case of a Philippine woman in her late twenties, diagnosed with spinal tuberculosis after surgical intervention due to medullary compression. The diagnosis was preceded by four months of unexplained back pain. Differential diagnoses included ulcer, liver-gallbladder disease, musculoskeletal causes, and cancer. This case highlights the importance of considering tuberculosis as a differential diagnosis in patients from high-endemic areas to avoid diagnostic delay and the risk of disease progression.
- 3 May 2024
- Published by Hindawi Limited in Case Reports in Infectious Diseases
- Vol. 2024, 1-3
Open AccessDiagnostic Delay of Spinal Tuberculosis Causing Medullary Compression
We present a case of a Philippine woman in her late twenties, diagnosed with spinal tuberculosis after surgical intervention due to medullary compression. The diagnosis was preceded by four months of unexplained back pain. Differential diagnoses included ulcer, liver-gallbladder disease, musculoskeletal causes, and cancer. This case highlights the importance of considering tuberculosis as a differential diagnosis in patients from high-endemic areas to avoid diagnostic delay and the risk of disease progression.
- 11 November 2022
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (2) , 602-605
Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation
We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.
- 11 November 2022
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (2) , 602-605
Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation
We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.